Fiscal Year 2025 Highlights - The company's average active community count increased by 14% to 164 in FY25[11] - The company's net debt to net capitalization finished below 40%[11] - The company's book value per share grew by 6% through profitability and $33 million in share buybacks[11] Operational Response - The company rebid labor and material costs, resulting in approximately $10,000 savings per home[16] - The company reduced headcount, achieving $12 million in run-rate savings[16] - The company sold land for strategic alignment, generating $63 million in FY25 proceeds and expecting over $100 million in FY26[16] - The company increased the lot option percentage by 4 points to 62%[16] Q4 2025 Results - The company's new home orders were 999, a decrease of 2.9% year-over-year[29] - The company's homebuilding revenue was $750.8 million, a decrease of 4.2% year-over-year[29] - The company's closings were 1,406, a decrease of 6.0% year-over-year[29] - The company's adjusted EBITDA was $63.8 million, a decrease of 31.5% year-over-year[29] - The company's homebuilding gross margin was 17.2%, a decrease of 320 bps year-over-year[29] Liquidity and Capitalization - The company's net debt to net capitalization was 39.5%[35] - The company's total liquidity was approximately $540 million, up approximately $35 million versus September 30, 2024[35]

Product & Technology - ESS launched the Energy Base, a new product featuring modular powertrains called the Iron Core, designed for gigawatt-hour storage capacity[11, 20] - The Energy Base extends duration up to 22 hours by scaling electrolyte volume, unlocking green baseload power and reducing $/kWh cost[29] - ESS iron flow battery modules are capable of storing up to 22 hours of energy[29] Market & Strategy - Data centers' electricity demand is estimated to grow to 800 TWh by 2026, putting pressure on infrastructure[33] - Power disruption accounts for 54% of impactful data center outages[36] - ESS products offer a safe, scalable, and cost-effective alternative to gas generators for data centers[34] Financial Performance - Q3 2025 revenue was $0.2 million, a 40% decrease compared to $0.4 million in Q3 2024[50] - Q3 2025 net loss was $10.4 million, a 54% improvement compared to $22.5 million in Q3 2024[50] - Adjusted EBITDA for Q3 2025 was a loss of $7.17 million, a 62% improvement compared to a loss of $18.87 million in Q3 2024[50, 52]

Q3 2025 Performance - Gross Merchandise Sales (GMS) reached $2.4 billion, an 11% year-over-year increase[16] - Excluding the impact of the Eras Tour, GMS growth would have been 24% year-over-year[16] - Revenue totaled $468 million, reflecting an 8% year-over-year growth[18] - Adjusted EBITDA was $67 million, a 21% increase year-over-year, with a 14% margin[19] Strategic Initiatives and Financial Position - Successfully completed an IPO and used the proceeds to pay down $750 million in debt[11] - The debt repayment is projected to save approximately $75 million in annual cash debt service costs[11, 46] - Net leverage decreased to 3.9x post-IPO[46] Market Opportunity and Scale - The company estimates a total addressable market of $194 billion today, with a future potential of $726 billion including adjacent categories[38] - Trailing twelve-month (TTM) GMS reached $9.4 billion[34] - The company has consistently maintained an approximately 20% service fee per transaction[32]

Investor Presentation Q3 2025 As of November 13, 2025 Safe Harbor Statement/Non-GAAP Measures All information in this presentation is as of November 13, 2025. Forward-Looking Statements Certain statements included in this presentation are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1996, as amended. Forward-looking statements are statements other than statements about historical fact. The forward looking statements ...

Financial Performance - Fiscal Year 2025 revenue reached a record $28.4 billion, a 4% year-over-year increase[8] - Non-GAAP earnings per share (EPS) for Fiscal Year 2025 were $9.42, a 9% year-over-year increase[8] - Non-GAAP gross margin for Fiscal Year 2025 was 48.8%, a 120 basis points increase year-over-year[8] - Applied Global Services (AGS) achieved record revenue, growing 3% year-over-year to $6.4 billion[12] - Semiconductor Systems Group revenue was $20.8 billion, a 4% year-over-year increase[12] Future Outlook - The company anticipates first quarter fiscal year 2026 revenue of approximately $6.85 billion, plus or minus $500 million[49] - The company anticipates first quarter fiscal year 2026 non-GAAP EPS of approximately $2.18, plus or minus $0.20[49] Capital Allocation - The company is committed to distributing 80-100% of free cash flow (FCF) to shareholders over time[40, 53] - As of the end of Fiscal Quarter 4 2025, $14.0 billion remained on the share repurchase authorization[40, 53]

Hyperfine Overview - Hyperfine's Swoop system is the first FDA-cleared, AI-powered portable MR brain imaging system, targeting a market opportunity exceeding $6 billion[4, 74] - The company's growth strategy is supported by the launch of the next-generation Swoop system and Optive AI software, which enhances image quality for ultra-low field MRI[4] - Hyperfine has secured approximately 200 patents related to its proprietary technology[9] Market and Expansion - The company is targeting expansion across multiple sites of care, including inpatient, outpatient, and community settings, with a total addressable market (TAM) potentially exceeding $16 billion[8] - Hyperfine has an installed base of over 190 Swoop systems globally[52] - The company estimates a potential US Swoop system revenue of $100 million for every 1.5% market penetration[54] Financial Performance - Q3 2025 revenue reached $3.4 million, representing a 27% sequential increase[58] - The effective average selling price (ASP) for the Swoop system in Q3 2025 was approximately $360,000[58] - Cash burn decreased to $5.9 million in Q3 2025, a 27% reduction compared to the previous quarter[59]

Financial Highlights - TMC has $165 million in liquidity as of November 13, 2025, excluding in-the-money warrants [8] - Potential proceeds from Class A and Class C warrants that are in-the-money today is approximately $54 million [14] - Q3 2025 operating loss was $55.3 million, compared to $19.9 million in Q3 2024 [84] - The company's cash balance increased mainly due to proceeds from warrants and stock options, with $7.1 million in proceeds in Q3 2025 and $12.8 million in October 2025 [11, 12] Resource and Production - A billion-tonne resource could supply the US with manganese for 330 years, cobalt for 95 years, nickel for 210 years, and copper for 5 years [18, 20] - The company estimates first production in Q4 2027 [65] - The PFS NPV is $5.5 billion, and the IA NPV is $18.1 billion, resulting in a combined NPV of $23.6 billion [62, 67] - The Pre-Feasibility Study (PFS) projects revenue of $595 per dry tonne of nodules, with an EBITDA of $254 per dry tonne (43% margin) [72, 73] Regulatory and Strategic - The US depends entirely on imports for primary nickel, manganese, and cobalt, and 45% for copper [15, 16] - NOAA is streamlining the review of applications for Exploration Licenses (ELs) and Commercial Recovery Permits (CRPs) [32] - The United States and Japan will collaborate on developing rare earth minerals from Japan's seafloor [25]

Company Overview & Strategy - HeartBeam aims to shift cardiac care from hospitals to home, similar to trends seen with glucose, blood pressure, and oxygen monitors[15, 16] - The company's synthesized 12-Lead ECG system, combined with on-demand cardiologist interpretation, is the foundation for a new cardiac care model[21] - HeartBeam is building an ecosystem around its core technology to deepen patient engagement and provide actionable insights for physicians[21, 23] - The company's near-term commercial strategy focuses on creating a new category, market entry through pilot programs, a focused commercial model, and patient retention[30] Regulatory & Clinical Milestones - HeartBeam received foundational FDA clearance for its system for arrhythmia assessment in December 2024[9, 13, 25] - FDA 510(k) clearance for the 12-Lead ECG Synthesis Software for arrhythmia assessment is anticipated in Q4 2025[13, 25, 34] - A pivotal clinical study (VALID-ECG) showed 93.4% overall diagnostic agreement for arrhythmia assessment[25] - New data presented at AHA Scientific Sessions in November 2025 supports HeartBeam's potential for early heart attack detection[27] Financial Performance (Q3 2025) - Total operating expenses were $5290 thousand[31] - Net loss was $5255 thousand, with an Earnings per Share (EPS) of $(0.15)[31] - Net cash used in operating activities was $3160 thousand, an 8% decrease quarter-over-quarter[31, 33] - Cash and cash equivalents and short-term investments totaled $1856 thousand as of September 30, 2025[31]

Market Opportunity and Growth - The total market for generative AI is projected to reach a five-year CAGR of 73.5% by 2028[5] - Worldwide IT services spending is expected to reach $2.1 trillion by 2027[6] - The digital business services market is estimated to reach $702 billion by 2027[6] - 90% of service providers will use generative AI for software development services by 2027[7] - Global spending on product engineering and operational technology services is forecasted to reach $334 billion by 2027[7] - Generative AI's annual spending worldwide is projected to reach $151 billion by 2027[7] Financial Performance - The company's Last Twelve Months (LTM) Q3'25 total revenue is $2.5 billion[34] - The company's revenue Compound Annual Growth Rate (CAGR) from 2014 to 2024 was 28.3%[34, 40] - The company's LTM Q3'25 revenue per IT professional is $90.3K[34] - The company's Q3'25 adjusted gross profit margin is 38.1%[34] - The company's Q3'25 adjusted profit from operations margin is 15.5%[34]

Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation November 2025 Important Notices & Disclaimers This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements we make regarding BioAtla's business plans and prospects; whet ...